Center for Immuno-Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Oncotarget. 2023 Aug 10;14:758-774. doi: 10.18632/oncotarget.28487.
With the rapid adoption of immunotherapy into clinical practice for HPV-associated malignancies, assessing tumor burden using "liquid biopsies" would further our understanding of clinical outcomes mediated by immunotherapy and allow for tailoring of treatment based on real-time tumor dynamics. In this review, we examine translational studies on peripheral surrogates of tumor burden derived from peripheral blood in HPV-associated malignancies, including levels and methylation of circulating tumor DNA (ctDNA), miRNA derived from extracellular vesicles, circulating tumor cells (CTCs), and HPV-specific antibodies and T cell responses. We review their utility as prognostic and predictive biomarkers of response to chemotherapy and radiation, with a focus on how they may inform and guide immunotherapies to treat locally advanced and metastatic HPV-associated malignancies. We also highlight unanswered questions that must be addressed to translate and integrate these peripheral tumor biomarkers into the clinic.
随着免疫疗法在 HPV 相关恶性肿瘤的临床实践中的迅速应用，使用“液体活检”来评估肿瘤负担将进一步加深我们对免疫疗法介导的临床结果的理解，并能够根据实时肿瘤动态来调整治疗方法。在这篇综述中，我们研究了源自 HPV 相关恶性肿瘤外周血的肿瘤负担的外周替代物的转化研究，包括循环肿瘤 DNA（ctDNA）的水平和甲基化、来自细胞外囊泡的 miRNA、循环肿瘤细胞（CTC）以及 HPV 特异性抗体和 T 细胞反应。我们综述了它们作为化疗和放疗反应的预后和预测生物标志物的效用，重点关注它们如何为治疗局部晚期和转移性 HPV 相关恶性肿瘤的免疫疗法提供信息和指导。我们还强调了必须解决的未解决问题，以将这些外周肿瘤生物标志物转化并整合到临床实践中。
